Cargando…

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

OBJECTIVE: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer. METHODS: Patients with HER2-negative breast cancer, who were pre-treated with anthracycline or taxanes i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Nanlin, Si, Yiran, Yue, Jian, Sun, Tingting, Wang, Xue, Jia, Zhuqing, Gao, Songlin, Li, Qiao, Shao, Yang, Wang, Jiayu, Luo, Yang, Ma, Fei, Xu, Binghe, Yuan, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330540/ https://www.ncbi.nlm.nih.gov/pubmed/33710812 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0463

Ejemplares similares

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

Bronchial Fistula: Rare Complication of Treatment with Anlotinib
por: DENG, Pengbo, et al.
Publicado: (2020)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
por: Su, Ning, et al.
Publicado: (2022)

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
por: Tang, Lina, et al.
Publicado: (2022)

The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia
por: Yang, Linlin, et al.
Publicado: (2023)

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
por: Wang, Tian, et al.
Publicado: (2022)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
por: Zhou, Lingxiao, et al.
Publicado: (2023)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
por: Hu, Ting, et al.
Publicado: (2020)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
por: Jiang, Bailing, et al.
Publicado: (2019)

The Value of Anlotinib in the Treatment of Intractable Brain Edema: Two Case Reports
por: Yang, Song, et al.
Publicado: (2021)

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
por: Li, Shiting, et al.
Publicado: (2023)

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
por: Ren, Biyong, et al.
Publicado: (2021)

Pneumothorax in lung cancer following anlotinib treatment: A case report
por: Yang, Lei
Publicado: (2022)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Case report of severe pneumothorax due to lung cancer treated with anlotinib
por: Lu, Haowei, et al.
Publicado: (2023)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
por: Song, Yan, et al.
Publicado: (2021)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

Successful treatment of advanced ovarian cancer with anlotinib: a case report
por: Zhang, Ping, et al.
Publicado: (2020)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review
por: Cheng, Ke, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer
por: Wu, Jiajun, et al.
Publicado: (2023)

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Xu, Huanhuan, et al.
Publicado: (2021)

Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer
por: Gao, Qin, et al.
Publicado: (2020)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
por: Gu, Yuanyuan, et al.
Publicado: (2022)

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mk7e41ptb6ant4bnepsvbl8m0s